Guardant Health, Inc. Stock price

Equities

GH

US40131M1099

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
17.45 USD -1.63% Intraday chart for Guardant Health, Inc. -8.11% -35.49%
Sales 2024 * 664M Sales 2025 * 803M Capitalization 2.12B
Net income 2024 * -401M Net income 2025 * -366M EV / Sales 2024 * 3.64 x
Net Debt 2024 * 292M Net Debt 2025 * 451M EV / Sales 2025 * 3.21 x
P/E ratio 2024 *
-5.2 x
P/E ratio 2025 *
-5.78 x
Employees 1,774
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.47%
More Fundamentals * Assessed data
Dynamic Chart
Guardant Health, Inc. Announces Results from the ECLIPSE Study Showing the Effectiveness of Its Shield Blood Test for Detecting Colorectal Cancer CI
Transcript : Guardant Health, Inc. Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 01:00 PM
Piper Sandler Cuts Price Target on Guardant Health to $30 From $40, Maintains Overweight Rating MT
UBS Adjusts Guardant Health Price Target to $32 From $45, Maintains Buy Rating MT
Canaccord Genuity Adjusts Price Target on Guardant Health to $45 From $50, Maintains Buy Rating MT
Guardant Health Q4 Adjusted Loss Narrows as Revenue Rises MT
Transcript : Guardant Health, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Earnings Flash (GH) GUARDANT HEALTH Posts Q4 Revenue $155.1M, vs. Street Est of $150.8M MT
Guardant Health, Inc. Provides Earnings Guidance for the Year 2024 CI
Guardant Health, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Guardant Health, Inc. Announces Resignation of Mr. Samir Kaul as Member of the Board and as Member of the Compensation Committee of the Board CI
Goldman Sachs Cuts Price Target on Guardant Health to $37 From $43, Maintains Buy Rating MT
Transcript : Guardant Health, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 03:45 PM
Guardant Health Reports Preliminary Q4 Revenue MT
EDX Medical maintains confident outlook; implements biopsy tests AN
More news
1 day-1.63%
1 week-8.11%
Current month-8.16%
1 month-22.17%
3 months-35.89%
6 months-38.64%
Current year-35.49%
More quotes
1 week
17.40
Extreme 17.395
19.46
1 month
17.40
Extreme 17.395
22.86
Current year
17.40
Extreme 17.395
27.61
1 year
17.40
Extreme 17.395
41.06
3 years
17.40
Extreme 17.395
169.43
5 years
17.40
Extreme 17.395
181.07
10 years
17.40
Extreme 17.395
181.07
More quotes
Managers TitleAgeSince
Founder 48 11-12-31
Founder 44 11-12-31
Chief Executive Officer 45 12-12-31
Members of the board TitleAgeSince
Director/Board Member 62 16-11-30
Director/Board Member 65 21-10-14
Director/Board Member 49 20-05-31
More insiders
Date Price Change Volume
24-03-18 17.45 -1.63% 2,146,690
24-03-15 17.74 -3.43% 2,460,239
24-03-14 18.37 -3.32% 2,209,334
24-03-13 19 +1.93% 1,542,613
24-03-12 18.64 -1.84% 1,306,295

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer globally through the use of its proprietary tests, vast data sets and advanced analytics. The Company has developed its Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer. It also has developed Guardant360 TissueNext tissue test for advanced-stage cancer, Guardant Reveal blood test to detect residual and recurring disease in early-stage cancer patients, and Guardant360 Response blood test to predict patient response to immunotherapy or targeted therapy eight weeks earlier than current standard-of-care imaging. The Company's GuardantINFORM platform is used to help biopharmaceutical companies accelerate precision oncology drug development through the use of this in-silico research platform to unlock further insights into tumor evolution and treatment resistance across various biomarker-driven cancers.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
17.45 USD
Average target price
41.76 USD
Spread / Average Target
+139.34%
Consensus
  1. Stock
  2. Equities
  3. Stock Guardant Health, Inc. - Nasdaq